Literature DB >> 3131439

Epidermal plasminogen activator is abnormal in cutaneous lesions.

P J Jensen1, J Baird, S Morioka, S Lessin, G S Lazarus.   

Abstract

To investigate the role of plasminogen activator (PA) in cutaneous disease, we have used biochemical and immunocytochemical techniques to examine PA in normal and lesional skin. In normal human dermis, tissue PA is the predominant PA activity; however, in normal epidermis, urokinase type PA is the predominant PA activity. In contrast, PA activity in epidermis from lesions of patients with a variety of cutaneous diseases was predominantly tissue type enzyme with a much smaller contribution from urokinase. Our patient population included individuals with benign chronic pemphigus, pemphigus vulgaris, pemphigus foliaceous, bullous pemphigoid, or psoriasis. Using rabbit antibody specific for tissue type PA, we have immunocytochemically localized this enzyme in lesions from individuals with the above disorders. Our results indicate that tissue PA is consistently elevated in cutaneous lesions with diverse etiology, pathology, and clinical presentation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131439     DOI: 10.1111/1523-1747.ep12461494

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Role of plasminogen activator in pemphigus vulgaris.

Authors:  J E Wilkinson; C A Smith; M M Suter; W Falchek; R M Lewis
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

2.  Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).

Authors:  J M Rox; J Reinartz; M D Kramer
Journal:  Arch Dermatol Res       Date:  1996-08       Impact factor: 3.017

3.  Differential expression of SKALP/Elafin in human epidermal tumors.

Authors:  H A Alkemade; H O Molhuizen; I M van Vlijmen-Willems; U J van Haelst; J Schalkwijk
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

4.  Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.

Authors:  B Lyons-Giordano; D Loskutoff; C S Chen; G Lazarus; M Keeton; P J Jensen
Journal:  Histochemistry       Date:  1994-02

5.  Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.

Authors:  Zhi Liu; Ning Li; Luis A Diaz; Michael Shipley; Robert M Senior; Zena Werb
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

6.  Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.

Authors:  J Reinartz; H Näher; H Mai; M D Kramer
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

7.  The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.

Authors:  M D Kramer; J Reinartz
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  The kidney is a major site of alpha(2)-antiplasmin production.

Authors:  P A Menoud; N Sappino; M Boudal-Khoshbeen; J D Vassalli; A P Sappino
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.

Authors:  E Schmidt; B Wehr; E M Tabengwa; S Reimer; E-B Bröcker; D Zillikens
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 10.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.